Biotech

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (" Aurinia " or the " Company ") is pleased to announce that the eight incumbent directors of the Company were elected at the Company's annual general meeting (the " Meeting ") held on June 7, 2021.

Detailed results of the vote by proxy for the election of directors are provided below:

Nominee

Votes For (%)

Votes Withheld (%)

George M. Milne

80.91

19.09

Peter Greenleaf

92.18

7.82

David R.W. Jayne

93.00

7.00

Joseph P. Hagan

87.15

12.85

Daniel G. Billen

95.64

4.36

R. Hector MacKay-Dunn

93.27

6.73

Jill Leversage

95.05

4.95

Timothy P. Walbert

89.56

10.44

In addition, following final tallies of votes, all other matters voted on at the Meeting were also approved . Voting results on all matters voted on at the Meeting will be filed on SEDAR at www.sedar.com and EDGAR at www.edgar.com .

About Aurinia

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company's head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

Investors:
Glenn Schulman, PharmD, MPH
Investor Relations & Corporate Communications, Aurinia
gschulman@auriniapharma.com

Media:
Dana Lynch
Corporate Communications, Aurinia
dlynch@auriniapharma.com

News Provided by Business Wire via QuoteMedia

FDA Approves JUVÉDERM® VOLUX XC for Improvement of Jawline Definition

JUVÉDERM ® VOLUX™ XC IS THE FIRST AND ONLY HYALURONIC ACID (HA) FILLER TO RECEIVE U.S. FDA APPROVAL FOR IMPROVING JAWLINE DEFINITION

Today, Allergan Aesthetics, an ABBVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM ® VOLUX™ XC for the improvement of jawline definition in adults over the age of 21 with moderate to severe loss of jawline definition. 1

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Gilead Sciences Announces Second Quarter 2022 Financial Results

Biktarvy Sales Increased 28% Year-Over-Year to $2.6 billion

Oncology Sales Increased 71% Year-Over-Year to $527 million

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Aptose Reports Results for the Second Quarter 2022

─ HM43239 Preliminary Response Rate of 43% Among R/R AML Patients with FLT3 Mutations Who Failed Prior Therapy with FLT3 inhibitors ─

─ HM43239 Complete Remissions and Safety Across Three Dose Levels and Multiple Genotypic Subpopulations ─

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

AMGEN TO WEBCAST INVESTOR MEETING AT WCLC 2022

Amgen (NASDAQ: AMGN) will host a webcast call for the investment community in conjunction with the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer (WCLC) at 12:00 p.m. ET on Monday Aug. 8, 2022. David M. Reese M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team, will discuss the data being presented on LUMAKRAS ® (sotorasib) in combination with immunotherapy and in combination with a SHP2 inhibitor in non-small cell lung cancer, as well as tarlatamab data in small cell lung cancer.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases

  • New strategic collaboration leverages Sosei Heptares' StaR ® technology and SBDD platform and AbbVie's extensive neuroscience expertise
  • Second collaboration with AbbVie follows 2020 agreement focused on inflammatory and autoimmune diseases
  • Sosei Heptares eligible to receive up to $80 million in upfront and near-term milestone payments and has potential to receive further downstream payments totalling up to US$1.2 billion, plus tiered royalties

Sosei Group Corporation ("the Company"; TSE: 4565) and ABBVie (NYSE: ABBV), a research-based global biopharmaceutical company, announce they have entered a new drug discovery collaboration and option-to-license agreement to discover, develop and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR) targets associated with neurological disease.

The new agreement will leverage Sosei Heptares' StaR ® technology and structure-based drug design (SBDD) platform and AbbVie's extensive neuroscience and disease area expertise. The agreement expands the breadth of the ongoing collaboration between Sosei Heptares and AbbVie, building on the first multi-target discovery agreement signed between the companies in June 2020, which is focused on the inflammatory and autoimmune disease areas.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

AMGEN ANNOUNCES WEBCAST OF 2022 SECOND QUARTER FINANCIAL RESULTS

Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Thursday, August 4, 2022 after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. PT . Participating in the call from Amgen will be Robert A. Bradway chairman and chief executive officer, and other members of Amgen's senior management team.

Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and the general public.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×